-
-
-
-
-
-
-
Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
-
-
-
-
-
-
-
Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
-
-
-
-
-
-
-
Johnson & Johnson receives FDA approval for CAPLYTA to treat depression
-
-
-
-
-
-
-
Johnson & Johnson recommends shareholders reject “mini-tender” offer by Tutanota
-
-
-
-
-
-
-
Johnson & Johnson Reports Q1 2025 Results
-
-
-
-
-
-
-
Biotech Q4 earnings preview: Goldman Sachs
-
-
-
-
-
-
-
Johnson&Johnson reports Q3 beat, raises sales guidance
-
1,158,425 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

